Latest market headlines for BIOCON on Terminal.
29-Oct-2026 08:47:01
ā¢ Ranked 13th among top 20 global employers in biotech, biopharma and pharma; 15th consecutive year on the list. ā¢ Cited for social responsibility, respect forā¦
14-Oct-2026 09:32:25
ā¢ Biocon has settled for launch of its Pertuzumab biosimilar across key markets. ā¢ Expected launch timeline: EU/UK in Q1 2027 and US in Q3 2028, with potentialā¦
14-Oct-2026 08:40:28
ā¢ Biocon has entered into a global patent settlement and licence agreement with Genentech for Pebrilzo (bPertuzumab). ā¢ Agreement resolves all pending patent dā¦
21-Sept-2026 08:28:05
BIOCON : EMA RECOMMENDS PERTUZUMAB BIOSIMILAR
08-Sept-2026 08:31:54
ā¢ Biocon signed partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil. ā¢ The agreement is for the country's Productive Development Partneā¦
29-Jun-2026 22:36:35
ā¢ Completed acquisition of 1,15,36,956 equity shares of Biocon Biologics Limited (BBL) from 127 selling shareholders ā¢ Allotted 87,86,362 equity shares of Biocā¦
15-Jun-2026 19:13:55
ā¢ Declaration under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. ā¢ Declares that none of the entities beloā¦